MARKET

KPTI

KPTI

Karyopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.23
-0.02
-0.13%
After Hours: 15.16 -0.07 -0.46% 17:21 08/07 EDT
OPEN
15.16
PREV CLOSE
15.25
HIGH
15.75
LOW
15.09
VOLUME
1.78M
TURNOVER
--
52 WEEK HIGH
29.61
52 WEEK LOW
8.02
MARKET CAP
1.11B
P/E (TTM)
-5.3555
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KPTI stock price target is 31.44 with a high estimate of 41.00 and a low estimate of 20.00.

EPS

KPTI News

More
Karyopharm Therapeutics Inc (KPTI) Q2 2020 Earnings Call Transcript
This is Ian Karp and I'm joined today by Dr. Michael Kauffman, Chief Executive Officer; Dr. Sharon Shacham, President and Chief Scientific Officer; Mr. Mike Mason, Chief Financial Officer; Mr. John Demaree, Chief Commercial Officer; and Mr. Christopher Primian
Motley Fool · 4d ago
Karyopharm Therapeutics EPS misses by $0.08, beats on revenue
Karyopharm Therapeutics (NASDAQ:KPTI): Q2 GAAP EPS of -$0.63 misses by $0.08. Revenue of $33.51M (+253.1% Y/Y) beats by $5.1M. Press Release
seekingalpha · 4d ago
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -10.53% and 19.57%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 4d ago
Karyopharm Therapeutics Q2 EPS $(0.63) Misses $(0.58) Estimate, Sales $33.51M Beat $27.42M Estimate
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.58) by 8.62 percent. This is a 11.27 percent increase over losses of $(0.71) per
Benzinga · 5d ago
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended June 30, 2020. In addition, Karyopharm highlighted select corporate milestones, inc
PR Newswire · 5d ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 27,300 shares of Karyopharm's common
PR Newswire · 5d ago
Top Small Cap Stocks for August 2020
Investopedia · 07/29 19:32
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About KPTI

Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.
More

Webull offers kinds of Karyopharm Therapeutics Inc stock information, including NASDAQ:KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.